Ventilation following established ARDS: a preclinical model framework to improve predictive power.

Area of Science:

• Pulmonary Medicine
• Translational Research
• Preclinical Models

Background:

• Effective pharmacological treatments for acute respiratory distress syndrome (ARDS) remain elusive, potentially due to limitations in current preclinical models.
• Existing models often focus on biological pathways rather than predicting clinical treatment effects.

Purpose of the Study:

• To develop and validate a novel mouse model for ARDS that incorporates therapeutic intervention and mechanical ventilation.
• To assess the efficacy of beta-agonist treatment and an anti-tumor necrosis factor (TNF) receptor 1 antibody in this new model.

Main Methods:

• Lung injury was induced in mice using intranasal lipopolysaccharide (LPS).
• At peak injury, mice received intratracheal terbutaline (a beta-agonist) or an anti-TNF receptor 1 antibody.
• Mice were then ventilated with moderate tidal volume (20 mL/kg) to induce secondary ventilator-induced lung injury (VILI).

Main Results:

• Ventilating LPS-injured mice at 20 mL/kg exacerbated lung injury compared to low tidal volume ventilation.
• Terbutaline failed to attenuate VILI in pre-injured mice, mirroring its lack of clinical efficacy.
• Anti-TNF receptor 1 antibody successfully attenuated secondary VILI in pre-injured lungs, demonstrating model treatability.

Conclusions:

• The developed mouse model accurately predicts the clinical inefficacy of terbutaline in ARDS.
• This model provides a practical framework for evaluating novel ARDS therapeutics by comparing them to clinically tested interventions.
• Adopting such models can help reduce the number of ineffective drugs entering clinical trials.